Today: 7 February 2026
Subscribe
Browse Category

Pharma Industry News 16 January 2026 - 6 February 2026

Merck (MRK) stock price rises as Enflonsia approval and insider filing keep attention on what’s next

Merck (MRK) stock price rises as Enflonsia approval and insider filing keep attention on what’s next

Merck shares rose 1.8% to $121.92 Friday after Health Canada approved its RSV preventive ENFLONSIA for infants. Investors are watching for an FDA decision on Keytruda later this month. Officer Chirfi Guindo filed to sell 20,000 shares valued at about $2.44 million. Guggenheim raised its price target to $140.
6 February 2026
·····
Eli Lilly stock price jumps 10% after-hours on upbeat 2026 forecast and Q4 beat

Eli Lilly stock price jumps 10% after-hours on upbeat 2026 forecast and Q4 beat

Eli Lilly shares jumped 10.4% to $1,107.12 in after-hours trading Wednesday after reporting fourth-quarter revenue up 43% to $19.29 billion and a 2026 profit outlook above Wall Street forecasts. The company expects 2026 revenue of $80–83 billion and non-GAAP earnings per share of $33.50–$35.00. Mounjaro sales reached $7.41 billion and Zepbound $4.26 billion for the quarter.
4 February 2026
·····
Pfizer stock (PFE) edges up ahead of Feb. 3 earnings as obesity pricing shifts and RSV dispute draw focus

Pfizer stock (PFE) edges up ahead of Feb. 3 earnings as obesity pricing shifts and RSV dispute draw focus

Pfizer shares rose 0.3% to $26.51 ahead of fourth-quarter and full-year 2025 results due Feb. 3. Analysts expect adjusted earnings of 57–58 cents per share on $16.7–16.9 billion revenue. Obesity drug price cuts and a UK ruling against Sanofi in an RSV dispute add pressure. Pfizer projects 2026 revenue of $59.5–62.5 billion, factoring in losses from COVID-19 products and patent expirations.
2 February 2026
···
Merck stock beats a falling market — here’s what investors watch before Feb. 3 earnings

Merck stock beats a falling market — here’s what investors watch before Feb. 3 earnings

Merck shares rose 1.78% to $110.27 Friday, nearing a 52-week high as trading volume topped 19.1 million, above average. The move came amid broader market declines after Donald Trump named Kevin Warsh to lead the Federal Reserve and December producer prices jumped 0.5%. Investors now await Merck’s earnings and guidance on Feb. 3.
31 January 2026
·····
Novo Nordisk stock rebounds after a bruising drop as investors turn to the next catalyst

Novo Nordisk stock rebounds after a bruising drop as investors turn to the next catalyst

Novo Nordisk shares rose 4.3% to 389.95 Danish crowns in Copenhagen by 1318 CET Thursday, recovering most of Wednesday’s 4% drop. The move follows an expanded diabetes cell-therapy partnership with Aspect Biosystems announced this week. Investors are awaiting Novo’s full-year results on Feb. 4 for further guidance.
22 January 2026
·····
AbbVie stock rises after-hours as Bernstein sticks with $225 target ahead of Feb. 4 earnings

AbbVie stock rises after-hours as Bernstein sticks with $225 target ahead of Feb. 4 earnings

AbbVie shares closed up 0.99% at $216.15 Wednesday, trading near typical volume ahead of its Feb. 4 earnings report. Bernstein’s Courtney Breen maintained a Market Perform rating and $225 target. Investors are watching for 2026 guidance and updates on AbbVie’s new drug performance. Details of a recent pricing deal with the Trump administration remain undisclosed.
22 January 2026
·····
ImmunityBio stock jumps before the open after FDA outlines next step for ANKTIVA filing

ImmunityBio stock jumps before the open after FDA outlines next step for ANKTIVA filing

New York, January 20, 2026, 08:14 (EST) — Premarket ImmunityBio (IBRX.O) shares rose about 27% to $7 in premarket trading on Tuesday, with about 4.1 million shares changing hands, after the company said it had made progress with the U.S. Food and Drug Administration on a path to revive a label-expansion push for its bladder cancer treatment ANKTIVA. (Public) The Culver City, California-based company said the FDA recommended it submit additional information that could support a resubmission of a supplemental biologics license application, or sBLA, for ANKTIVA plus BCG in BCG-unresponsive non-muscle invasive bladder cancer with papillary tumors. It said
20 January 2026
·····
Roche stock in focus: Goldman flips to Neutral, UBS lifts target as Jan 29 results loom

Roche stock in focus: Goldman flips to Neutral, UBS lifts target as Jan 29 results loom

Zurich, Jan 18, 2026, 17:32 CET — Market closed Roche Holding Ltd’s non-voting shares ended Friday up 0.93%, closing at 348.90 Swiss francs. The stock has remained within a narrow band heading into Monday’s session. (MarketScreener) Goldman Sachs upgraded Roche from “sell” to “neutral” and boosted its 12-month price target to 365 Swiss francs, up from 260. The bank highlighted a smoother slate of clinical milestones expected in 2026, following late-2025 trial results. It singled out fenebrutinib, Roche’s experimental multiple sclerosis treatment, and the breast cancer drug giredestrant as key growth drivers. Despite the optimism, Goldman Sachs held back on
18 January 2026
·····
ImmunityBio stock price surges on ANKTIVA sales pop — what IBRX investors watch next

ImmunityBio stock price surges on ANKTIVA sales pop — what IBRX investors watch next

New York, Jan 17, 2026, 06:10 EST — Markets have closed for the day. Shares of ImmunityBio Inc (IBRX.O) surged almost 40% on Friday following a strong boost in preliminary sales for its bladder cancer treatment ANKTIVA, alongside fresh trial updates. The stock finished at $5.52, marking a 39.9% gain, after swinging between $4.09 and $6.44 on heavy volume of roughly 182 million shares. The rally is significant as ImmunityBio works to show ANKTIVA can shift from a niche debut to consistent commercial success. Investors are also focused on whether the drug can tap into a broader first-line bladder cancer
17 January 2026
·····
BridgeBio Pharma (BBIO) stock edges up after $550 million convertible notes pricing — what investors watch next

BridgeBio Pharma (BBIO) stock edges up after $550 million convertible notes pricing — what investors watch next

New York, January 16, 2026, 14:57 EST — Regular session Shares of BridgeBio Pharma Inc edged up 0.5% to $76.66 Friday afternoon, following the announcement of a $550 million convertible notes sale. The stock swung between $75.87 and $78.12, with roughly 5.9 million shares changing hands. (BridgeBio Investor Relations) This financing matters because it reshapes BridgeBio’s balance sheet in one go, extending maturities and cutting cash interest just as the company ramps up spending on commercialization and development. Convertible notes offer a well-known setup for equity holders. They’re debt instruments that can convert into shares down the line at a
16 January 2026
·····
ImmunityBio stock jumps in premarket as $113 mln ANKTIVA sales update fuels rally

ImmunityBio stock jumps in premarket as $113 mln ANKTIVA sales update fuels rally

New York, January 16, 2026, 05:00 (EST) — Premarket ImmunityBio, Inc. shares jumped roughly 32% to $3.95 in premarket trading Friday following the biotech’s report of a steep rise in preliminary 2025 product revenue. The company also highlighted recent regulatory approvals in Saudi Arabia. (Business Wire) The update offers investors an early glimpse of how quickly ANKTIVA is growing commercially, ahead of the company’s audited annual results. It also provides fresh figures tied to the company’s expansion into new markets—the section traders have been eager to scrutinize in the filings. (Business Wire) ImmunityBio reported preliminary net product revenue of roughly
16 January 2026
····
1 2 3 … 9

Stock Market Today

South32 share price drops 4% in ASX rout — what investors watch before results

South32 share price drops 4% in ASX rout — what investors watch before results

7 February 2026
Sydney, Feb 7, 2026, 17:39 AEDT — Market closed. South32 Ltd shares (S32.AX) closed down 4.1% at A$4.41 on Friday, hit by the same risk-off wave that pushed Australian miners sharply lower. The stock traded between A$4.37 and A$4.51 and was down 19 cents from the prior close of A$4.60. (Intelligent Investor) With markets shut for the weekend, the move leaves South32 on the watchlist going into Monday’s open as investors reassess exposure to metals and mining names. The S&P/ASX 200 ended the week down 1.81%. (Morningstar) The benchmark fell 2% on Friday and almost A$70 billion was wiped off
Wesfarmers share price: what to watch on ASX next week as results loom

Wesfarmers share price: what to watch on ASX next week as results loom

7 February 2026
Wesfarmers shares closed down 1.33% at A$85.04 on Friday, following a sharp drop in the S&P/ASX 200, which fell 2% for its steepest one-day loss in 10 months. Investors are watching for Australia’s household spending data next week and Wesfarmers’ half-year results due Feb. 19.
Go toTop